Allergic rhinitis
Conditions
Interventions
Group B:Nasal cavity irrigation and conventional treatment
Group C:Nasal cavity flushing, conventional treatment and Panfuxu
Sponsors
Children's Hospital Affiliated to Zhejiang University School of Medicine
Eligibility
Sex/Gender
All
Age
3 Years to 12 Years
Inclusion criteria
Inclusion criteria: 1. Aged >= 3 years, and 5 times/year; 5. The volume of adenoids accounts for <= 70% of the nasopharynx; 6. Have not used anti-allergic drugs such as glucocorticoids, antihistamines, leukotriene receptor antagonists in the past 2 weeks; 7. The children and their guardians have good compliance. The subjects of the experimental group need to be willing to receive Panfuxu treatment, be able to cooperate with the drug treatment for 1 to 3 months, voluntarily participate in this clinical study and sign an informed consent.
Exclusion criteria
Exclusion criteria: 1. Have had nasal surgery, nasal deformities, etc.; 2. With nasal polyps, asthma, nasal septum deviation and other causes of nasal congestion; 3. Acute upper respiratory tract infection in the past 2 weeks; 4. Related metabolic disorders, cardiovascular diseases, nervous system diseases, blood system diseases, gastrointestinal diseases, cerebrovascular diseases and respiratory diseases, etc.; 5. Subjects with severe liver and kidney dysfunction and allergies; 6. Subjects deemed unsuitable by other researchers to participate in the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Symptom score;Serum immunoglobulin total IgE, IgA, IgG, IgM;Number and percentage of eosinophils;Lymphocytes CD3, CD16, CD56, CD19, CD8, CD4;Cytokines IL2, IL4, IL6, IL10, TNF, INF-r levels; | — |
Countries
China
Contacts
Public ContactFu Yong
Children's Hospital Affiliated to Zhejiang University School of Medicine
Outcome results
None listed